A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer

D. H. Johnson, J. C. Ruckdeschel, J. H. Keller, G. H. Lyman, G. J. Kallas, J. Macdonald, R. C. DeConti, J. Lee, Q. S. Ringenberg, W. P. Patterson, H. M. Lazarus, J. Lokich

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In a randomized multi-center study, 83 patients with small cell lung cancer were randomly assigned to treatment with cisplatin 100 mg/m2 intravenously (IV) day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3 or cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3. Both regimens were repeated every 4 weeks. Prior to randomization, patients were stratified by extent of disease, performance status, and gender. A total of 41 patients were randomly assigned to the parenteral treatment only regimen, and 42 patients received cisplatin and IV/oral etoposide therapy. Both treatment arms were comparable regarding patient characteristics. Limited disease (LD) patients constituted 52% and 49% of the patient population for the oral and IV etoposide regimens, respectively. The overall complete response (CR) and partial response (PR) rate was 50% (95% confidence interval [CI] 35% to 65%) for the oral etoposide regimen and 59% (95% CI 44% to 74%) for the IV etoposide regimen (P = 0.438). For both regimens, 55% of the LD patients achieved either CR or PR. Time to progression and survival were comparable for both treatment arms. Hematologic toxicity was comparable in both treatment arms, with 80% of patients experiencing grade 3 or 4 neutropenia or thrombocytopenia. Moderate to severe anemia and weight loss were more predominant with the IV than with the oral regimen.

Original languageEnglish (US)
Pages (from-to)245-249
Number of pages5
JournalCancer
Volume67
Issue number1 SUPPL.
StatePublished - 1991

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Cisplatin
Therapeutics
Confidence Intervals
Random Allocation
Neutropenia
Thrombocytopenia
Anemia
Weight Loss
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Johnson, D. H., Ruckdeschel, J. C., Keller, J. H., Lyman, G. H., Kallas, G. J., Macdonald, J., ... Lokich, J. (1991). A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer, 67(1 SUPPL.), 245-249.

A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. / Johnson, D. H.; Ruckdeschel, J. C.; Keller, J. H.; Lyman, G. H.; Kallas, G. J.; Macdonald, J.; DeConti, R. C.; Lee, J.; Ringenberg, Q. S.; Patterson, W. P.; Lazarus, H. M.; Lokich, J.

In: Cancer, Vol. 67, No. 1 SUPPL., 1991, p. 245-249.

Research output: Contribution to journalArticle

Johnson, DH, Ruckdeschel, JC, Keller, JH, Lyman, GH, Kallas, GJ, Macdonald, J, DeConti, RC, Lee, J, Ringenberg, QS, Patterson, WP, Lazarus, HM & Lokich, J 1991, 'A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer', Cancer, vol. 67, no. 1 SUPPL., pp. 245-249.
Johnson, D. H. ; Ruckdeschel, J. C. ; Keller, J. H. ; Lyman, G. H. ; Kallas, G. J. ; Macdonald, J. ; DeConti, R. C. ; Lee, J. ; Ringenberg, Q. S. ; Patterson, W. P. ; Lazarus, H. M. ; Lokich, J. / A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. In: Cancer. 1991 ; Vol. 67, No. 1 SUPPL. pp. 245-249.
@article{f2e72b96294d4f84a0373360f88f9f38,
title = "A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer",
abstract = "In a randomized multi-center study, 83 patients with small cell lung cancer were randomly assigned to treatment with cisplatin 100 mg/m2 intravenously (IV) day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3 or cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3. Both regimens were repeated every 4 weeks. Prior to randomization, patients were stratified by extent of disease, performance status, and gender. A total of 41 patients were randomly assigned to the parenteral treatment only regimen, and 42 patients received cisplatin and IV/oral etoposide therapy. Both treatment arms were comparable regarding patient characteristics. Limited disease (LD) patients constituted 52{\%} and 49{\%} of the patient population for the oral and IV etoposide regimens, respectively. The overall complete response (CR) and partial response (PR) rate was 50{\%} (95{\%} confidence interval [CI] 35{\%} to 65{\%}) for the oral etoposide regimen and 59{\%} (95{\%} CI 44{\%} to 74{\%}) for the IV etoposide regimen (P = 0.438). For both regimens, 55{\%} of the LD patients achieved either CR or PR. Time to progression and survival were comparable for both treatment arms. Hematologic toxicity was comparable in both treatment arms, with 80{\%} of patients experiencing grade 3 or 4 neutropenia or thrombocytopenia. Moderate to severe anemia and weight loss were more predominant with the IV than with the oral regimen.",
author = "Johnson, {D. H.} and Ruckdeschel, {J. C.} and Keller, {J. H.} and Lyman, {G. H.} and Kallas, {G. J.} and J. Macdonald and DeConti, {R. C.} and J. Lee and Ringenberg, {Q. S.} and Patterson, {W. P.} and Lazarus, {H. M.} and J. Lokich",
year = "1991",
language = "English (US)",
volume = "67",
pages = "245--249",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer

AU - Johnson, D. H.

AU - Ruckdeschel, J. C.

AU - Keller, J. H.

AU - Lyman, G. H.

AU - Kallas, G. J.

AU - Macdonald, J.

AU - DeConti, R. C.

AU - Lee, J.

AU - Ringenberg, Q. S.

AU - Patterson, W. P.

AU - Lazarus, H. M.

AU - Lokich, J.

PY - 1991

Y1 - 1991

N2 - In a randomized multi-center study, 83 patients with small cell lung cancer were randomly assigned to treatment with cisplatin 100 mg/m2 intravenously (IV) day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3 or cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3. Both regimens were repeated every 4 weeks. Prior to randomization, patients were stratified by extent of disease, performance status, and gender. A total of 41 patients were randomly assigned to the parenteral treatment only regimen, and 42 patients received cisplatin and IV/oral etoposide therapy. Both treatment arms were comparable regarding patient characteristics. Limited disease (LD) patients constituted 52% and 49% of the patient population for the oral and IV etoposide regimens, respectively. The overall complete response (CR) and partial response (PR) rate was 50% (95% confidence interval [CI] 35% to 65%) for the oral etoposide regimen and 59% (95% CI 44% to 74%) for the IV etoposide regimen (P = 0.438). For both regimens, 55% of the LD patients achieved either CR or PR. Time to progression and survival were comparable for both treatment arms. Hematologic toxicity was comparable in both treatment arms, with 80% of patients experiencing grade 3 or 4 neutropenia or thrombocytopenia. Moderate to severe anemia and weight loss were more predominant with the IV than with the oral regimen.

AB - In a randomized multi-center study, 83 patients with small cell lung cancer were randomly assigned to treatment with cisplatin 100 mg/m2 intravenously (IV) day 1 and etoposide 120 mg/m2 IV days 1, 2, and 3 or cisplatin 100 mg/m2 IV day 1 and etoposide 120 mg/m2 IV day 1 and 240 mg/m2 orally days 2 and 3. Both regimens were repeated every 4 weeks. Prior to randomization, patients were stratified by extent of disease, performance status, and gender. A total of 41 patients were randomly assigned to the parenteral treatment only regimen, and 42 patients received cisplatin and IV/oral etoposide therapy. Both treatment arms were comparable regarding patient characteristics. Limited disease (LD) patients constituted 52% and 49% of the patient population for the oral and IV etoposide regimens, respectively. The overall complete response (CR) and partial response (PR) rate was 50% (95% confidence interval [CI] 35% to 65%) for the oral etoposide regimen and 59% (95% CI 44% to 74%) for the IV etoposide regimen (P = 0.438). For both regimens, 55% of the LD patients achieved either CR or PR. Time to progression and survival were comparable for both treatment arms. Hematologic toxicity was comparable in both treatment arms, with 80% of patients experiencing grade 3 or 4 neutropenia or thrombocytopenia. Moderate to severe anemia and weight loss were more predominant with the IV than with the oral regimen.

UR - http://www.scopus.com/inward/record.url?scp=0026018602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026018602&partnerID=8YFLogxK

M3 - Article

C2 - 1845847

AN - SCOPUS:0026018602

VL - 67

SP - 245

EP - 249

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1 SUPPL.

ER -